Ikaros、IRF4和PSMD10蛋白定量表达预测VRD治疗多发性骨髓瘤患者生存
本研究在174例接受VRD方案的新诊断多发性骨髓瘤患者中,用毛细管纳米免疫分析法检测CD138纯化样本中12种药物作用机制相关蛋白。多因素Cox模型显示高PSMD10、高Ikaros、低IRF4及高危细胞遗传学与更短TTP和PFS独立相关。
要点
- 高PSMD10和高Ikaros蛋白表达与VRD治疗患者更短TTP和PFS独立相关。
- 低IRF4蛋白表达与更短TTP和PFS独立相关。
- 高危细胞遗传学同样是TTP和PFS的独立不良预后因素。
核心结论
- 检测VRD药物作用机制相关蛋白有助于预测多发性骨髓瘤治疗结局。
研究设计与样本
- 研究纳入174例按PETHEMA/GEM2012研究治疗的新诊断多发性骨髓瘤患者,用毛细管纳米免疫分析法检测CD138纯化样本中12种蛋白。
主要发现
- 5种蛋白酶体组分中PSMD1、PSMD4和PSMD10高表达对生存有负面影响。
- 伊沙佐米作用机制相关5种蛋白与TTP相关:cereblon和IRF4低表达、Ikaros和AGO2及Aiolos高表达与更短TTP显著相关。
- 糖皮质激素受体水平本身对预后无显著影响,但XPO1/GCR比值高与更短TTP和PFS相关。
临床怎么用
- 可考虑检测PSMD10、Ikaros和IRF4蛋白表达以辅助判断VRD治疗患者的预后风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The search for biomarkers based on the mechanism of drug action has not been thoroughly addressed in the therapeutic approaches to multiple myeloma (MM), mainly because of the difficulty in analyzing proteins obtained from purified plasma cells. Here, we investigated the prognostic impact of the expression of 12 proteins involved in the mechanism of action of bortezomib, lenalidomide, and dexamethasone (VRD), quantified by capillary nanoimmunoassay, in CD138-purified samples from 174 patients with newly diagnosed MM treated according to the PETHEMA/GEM2012 study. A high level of expression of 3 out of 5 proteasome components tested (PSMD1, PSMD4, and PSMD10) negatively influenced survival. The 5 analyzed proteins involved in lenalidomide's mode of action were associated with time to progression (TTP); low levels of cereblon and IRF4 protein and high levels of Ikaros, AGO2, and Aiolos were significantly associated with shorter TTP. Although the glucocorticoid receptor (GCR) level by itself had no significant impact on MM prognosis, a high XPO1 (exportin 1)/GCR ratio was associated with shorter TTP and progression-free survival (PFS). The multivariate Cox model identified high levels of PSMD10 (hazard ratio [HR] TTP, 3.49; P = .036; HR PFS, 5.33; P = .004) and Ikaros (HR TTP, 3.01, P = .014; HR PFS, 2.57; P = .028), and low levels of IRF4 protein expression (HR TTP, 0.33; P = .004; HR PFS, 0.35; P = .004) along with high-risk cytogenetics (HR TTP, 3.13; P < .001; HR PFS, 2.69; P = .002), as independently associated with shorter TTP and PFS. These results highlight the value of assessing proteins related to the mechanism of action of drugs used in MM for predicting treatment outcome.
引用
- Misiewicz-Krzeminska I, de Ramón C, Corchete LA, et al. Quantitative expression of Ikaros, IRF4, and PSMD10 proteins predicts survival in VRD-treated patients with multiple myeloma. Blood Adv. 2020. PMID: 33284947. doi:10.1182/bloodadvances.2020002711
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。